Home > Rheumatology > ACR 2019 > What is Hot in Systemic Lupus Erythematosus > Anifrolumab Succeeds in Second Phase 3 Trial in SLE

Anifrolumab Succeeds in Second Phase 3 Trial in SLE

Presented By
Prof. Eric Morand, Prof. Richard Furie
ACR 2019
Phase 3, TULIP

The randomised, double-blind, placebo-controlled TULIP 2 trial belongs to the rare phase 3 trials in which a biologic, in this case the type 1 interferon blocker anifrolumab, succeeds in meeting its primary endpoint, a composite lupus assessment response [1].

Anifrolumab is a human monoclonal antibody that binds the type 1 interferon receptor subunit 1. Type 1 interferons play a key role in the pathogenesis of systemic lupus erythematosus (SLE), as these cytokines are involved in the inflammatory pathways [2]. Between 60% and 80% of adults with SLE have an increased type 1 interferon gene signature, which has been shown to correlate with disease activity [3,4]. Therefore, type 1 interferons are an interesting target for the therapy of SLE. In the TULIP 2 study, 180 patients with moderate-to-severe SLE were randomly assigned to receive anifrolumab (300 mg intravenously) or placebo every 4 weeks for 48 weeks. The primary endpoint of the trial was a differenc...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on